M. Hernández

Differentiation stage of myeloma plasma cells: biological and clinical significance

B. Barlogie, G. Morgan, F. Prósper, 2017, Leukemia.

Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.

B. Barlogie, A. Órfão, N. Puig, 2016, Blood.

A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.

D. Esseltine, M. Terol, F. Prósper, 2004 .

Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma

H. Johnsen, M. Terol, M. Pérez‐Andrés, 2011, Leukemia.

Are myeloma patients with renal failure candidates for autologous stem cell transplantation?

C. Solano, J. Maldonado, J. S. San Miguel, 2000, The hematology journal : the official journal of the European Haematology Association.

A PETHEMA study of high-dose therapy/stem cell support (HDT), including tandem transplant, in primary refractory multiple myeloma (MM): Identification of two populations with different outcomes

J. Bladé, J. Lahuerta, R. García-Sanz, 2007 .

Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA/GEM trial

A. Oriol, J. Bladé, J. Lahuerta, 2017, Leukemia.